CLOPIDOGREL FOR SELECTIVE MYOCARDIAL REVASCULARIZATION
https://doi.org/10.15829/1560-4071-2016-3-97-100
Abstract
The article focuses on the practical issues of selective revascularization of myocardium, including the specifics of procedure and patients characteristics, whom this intervention is at most indicated. The emphasis is done on antiplatelet therapy, its timing related to the procedure itself, and on the recommended drugs. The data is provided from the point of evidence based medicine — recent European Guidelines.
About the Author
N. V. Teplova
N.I. Pirogov Russian National Research Medical University
Russian Federation
Moscow
Russian Federation
Moscow
References
1. 2014 ESC/EACTS Guidelines on myocardial revascularization (Russian translation). Russ J Cardiol 2015, 2 (118): 5-81. Russian (Рекомендации ESC/EACTS по реваскуляризации миокарда 2014. Российский кардиологический журнал 2015, 2 (118): 5-81).
2. Min JK, Dunning A, Lin FY, et al. Age- and sex-related differences in all-cause mortality risk based on coronary computed tomography angiography findings results from the International Multicenter CONFIRM (Coronary CT Angiography Evaluation for Clinical Outcomes: An International Multicenter Registry) of 23,854 patients without known coronary artery disease. J Am Coll Cardiol 2011; 58(8): 849-60.
3. Hachamovitch R, Rozanski A, Shaw LJ, et al. Impact of ischaemia and scar on the therapeutic benefit derived from myocardial revascularization vs. medical therapy among patients undergoing stress-rest myocardial perfusion scintigraphy. Eur Heart J 2011; 32(8): 1012-24.
4. Gordeev IG, Taratukhin EO, Shaydyuk OYu. Clinical Physiology and Pharmacology of Clotting. Moscow, Silicea-Poligraf, 2013, 128p. Russian (Гордеев ИГ, Таратухин ЕО, Шайдюк О.Ю. Клиническая физиология и фармакология гемостаза. М.: Силицея-Полиграф. 2013, 128с).
5. Hao PP, Zhang MX, Li RJ, et al. Clopidogrel 150 vs. 75 mg per day in patients undergoing percutaneous coronary intervention: a meta-analysis. J Throm Haemost 2011 Apr; 9: 627-37.
6. Bonello-Palot N, Armero S, Paganelli F, et al. Relation of body mass index to high on-ntreatment platelet reactivity and of failed clopidogrel dose adjustment according to platelet reactivity monitoring in patients undergoing percutaneous coronary intervention. Am J Cardiol 2009; 104: 1511-5.
7. Ned RM. Genetic Testing for CYP450 Polymorphisms to Predict Response to Clopidogrel: current evidence and test availability. Application: Pharmacogenomics. PLOS Currents Evidence on Genomic Tests. 2010 Sep 20. Ed.1. doi: 10.1371/currents.RRN1180.
8. Patti G, Grieco D, et al. High Versus Standard Clopidogrel Maintenance Dose After Percutaneous Coronary Intervention and Effects on Platelet Inhibition, Endothelian Function, and Inflammation. Results of the ARMIDA-150 mg (Antiplatelet Therapy for Reduction of Myocardial Damage During Angioplasty) Randomized Study. J Am Coll Cardiol 2011; 57: 771-8.
Review
For citations:
Teplova N.V. CLOPIDOGREL FOR SELECTIVE MYOCARDIAL REVASCULARIZATION. Russian Journal of Cardiology. 2016;(3):97-100. (In Russ.) https://doi.org/10.15829/1560-4071-2016-3-97-100
Views:
791
Email this article 